Anavex Life Sciences

Day range

$1.27 – $1.31

Open

$1.30

Prev close

$1.33

Volume

419.53K

Market cap

$123.29M

Shares out

92.7M

P/E

—

P/S

—

P/B

1.10

P/FCF

—

ROE

-11.6%

ROA

-10.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Regulatory decisionOct 15, 2026

  On October 15, 2026, Anavex Life Sciences Corp. (the "Company") issued a press release announcing that it received notification from the U.S. Food and Drug Administration that the Company may proceed with its planned clinical study under its investigational new drug application for blarcamesine in Fragile X syndrome.

• Executive compensation changeSep 28, 2026

  As a result of the Board Change CIC, all outstanding and unvested awards granted under the Incentive Plans, including all outstanding and unvested awards granted to Ms. Boenisch, immediately became fully vested and exercisable in accordance with the terms of the applicable Incentive Plan and applicable award agreement.

• Listing compliance regainedSep 2, 2026

  On September 2, 2026, the Company issued a press release announcing that the Company has received confirmation from Nasdaq that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1).

• Activist investor campaignAug 3, 2026

  The Press Release includes an open letter to Anavex's stockholders responding to the preliminary proxy statement filed by PVG Asset Management Corporation and Patrick S. Adams, which seeks to replace the entire Anavex Board.

• Preliminary resultsJul 30, 2026

  On July 30, 2026, Anavex Life Sciences Corp. (the "Company") issued a press release reporting preliminary financial results for its second quarter ended March 30, 2026 (the "Press Release"). The preliminary financial results in the Press Release are subject to completion of the Company's financial closing procedures.

Days to cover

13.6

Short interest

13.57M

Avg volume

1M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL
  negativeGlobeNewswire Inc.· Oct 21, 2026
• ROSEN, RECOGNIZED TRIAL ATTORNEYS, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL
  negativeGlobeNewswire Inc.· Oct 18, 2026
• AVXL Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Anavex Life Sciences Corp. Class Action Lawsuit
  negativeGlobeNewswire Inc.· Oct 13, 2026
• ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL
  negativeGlobeNewswire Inc.· Oct 11, 2026
• ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
  negativeGlobeNewswire Inc.· Oct 11, 2026